The members of deutraMed’s Scientific Advisory Board draw on a wide array of deuterium expertise and professional experience to advise the company on its science and innovation-focused activities. They meet periodically to peer review the company’s scientific work, provide expert input on research proposals, and share ideas for the exploration of new breakthrough innovations.
Dr. Porwoll has had a close association with deutraMed that includes service on the Board of Directors and advisory services to expand the company’s deuterium capabilities in both business and science. As the former President of Aldrich and VP of Supply Chain of Sigma Aldrich, Dr. Porwoll’s knowledge of customer requirements, products and technical isotopic expertise is world-class. He has developed, manufactured and managed various stable isotope production systems, including those with deuterium.
Dr. Miller has helped guide the scientific direction of deutraMed since its inception. During a more than 40-year career, he has gained extensive experience in hydrogen isotope separation, deuterium oxide technology and nuclear energy. He is the retired former head of the Hydrogen Isotopes Group of Atomic Energy of Canada Limited and is a listed inventor on numerous patents who is recognized as an expert in the field of deuterium oxide technology. Dr. Miller has a B.Sc. in Applied Chemistry from the University of Glasgow and a Ph.D. in Chemical Engineering from the University of London (Imperial College). He is a Past President of the Canadian Society for Chemical Engineering.
Dr. Murphy has been engaged with deutraMed since 2017, guiding the development of deuterated organic synthesis processes. His research is focused on organic chemistry, specifically the development of hypervalent iodine reagents. These reagents are key to his work developing new methods for carbene formation, C-C bond formation and α-carbonyl functionalization – chemistry that in turn is used to develop designer electrolytes for battery technologies and to target natural medicinal products.
Professor Gris began his association with deutraMed in 2020, in the field Bio-Pharmaceuticals. A member of the Immunology Program at the University of Sherbrooke, he is researching neuro-immune interactions during healthy state and disease. Professor Gris earned a Masters degree and Ph.D. in Neuroscience at Dr. Lynn Weaver's laboratory at the University of Western Ontario, where he discovered that the influx of neutrophils is detrimental for recovering after spinal cord injury.
Ms. Stuart has contributed to scientific innovations and intellectual property management at deutraMed since its inception. Her work at the company has included research into the use of deuterium in semiconductors and opportunity creation in deuterated pharmaceutical contract research projects. A University of Toronto National Scholar, Ms. Stuart is currently completing her MASc in Biomedical Engineering with a focus on machine learning in nanomedicine at U of T’s Frank Gu Lab. Her experience extends across computational materials research, medical device development, intellectual property management, and industrial chemicals. In addition, she has explored clinical challenges in contact lens fitting through advanced numerical simulations with collaborators at the University of Liverpool.